Video Experimental Relacionado
Updated: Jun 30, 2026
09:04
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
Riesgo de enfermedades cardiovasculares asociadas con las preparaciones orales de progestagenos con indicaciones
Lancet (London, England)
|November 24, 1999
Resumen
Las preparaciones de progestágenos para uso terapéutico aumentan significativamente el riesgo de tromboembolismo venoso. Sin embargo, estos tratamientos no parecen aumentar el riesgo de accidente cerebrovascular o infarto de miocardio.
Área de la Ciencia:
- Farmacovigilancia y farmacovigilancia también.
- Salud Cardiovascular La salud cardiovascular.
- Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos Trastornos trombóticos
Sus antecedentes:
- Los progestagenos son ampliamente utilizados para diversas indicaciones terapéuticas.
- Comprender el perfil de seguridad de los preparados de progestagenos es crucial para la práctica clínica.
- Los datos existentes sobre la asociación entre los progestagenos y los eventos cardiovasculares adversos importantes son limitados.
Objetivo del estudio:
- Investigar la asociación entre el uso de preparaciones de progestagenos con indicaciones terapéuticas y el riesgo de eventos cardiovasculares adversos importantes.
- Para examinar específicamente los riesgos de tromboembolismo venoso, accidente cerebrovascular y infarto de miocardio.
Principales métodos:
- Se utilizaron datos del Estudio Colaborativo de la Organización Mundial de la Salud (OMS).
- Se analizó la incidencia de tromboembolismo venoso, accidente cerebrovascular y infarto de miocardio en relación con el uso de progestagenos.
- Empleó métodos epidemiológicos para evaluar las asociaciones de riesgo.
Principales resultados:
- Las preparaciones de progestágenos con indicaciones terapéuticas se asociaron significativamente con un mayor riesgo de tromboembolismo venoso.
- No se encontró una asociación significativa entre el uso de progestagenos y el riesgo de accidente cerebrovascular.
- Del mismo modo, no se observó una asociación significativa entre el uso de progestagenos y el riesgo de infarto de miocardio.
Conclusiones:
- El uso de preparaciones de progestágeno con fines terapéuticos conlleva un riesgo notable de tromboembolismo venoso.
- Los médicos deben considerar cuidadosamente este riesgo al prescribir progestagenos.
- Puede ser necesario realizar más investigaciones para explorar los mecanismos subyacentes a esta asociación.
Videos de Conceptos Relacionados
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...